Skip to main content

Gibson Christopher's Form 4 filing

Recursion Pharmaceuticals, Inc. (RXRX) · filed Jun 6, 2022

Accession no.
0001209191-22-034743
Filed
Jun 6, 2022
Trade date
Jun 2, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 10 non-derivative transactions and 5 derivative transactions. Open-market sales total $257.5K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gibson ChristopherCIK 0001856369Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 2, 2022Class A Common StockMOption exerciseAcquired+31,250$2.48+$77,500537,458Direct
Jun 2, 2022Class A Common StockSSaleDisposed−21,190$5.87−$124,385.3516,268Direct
Jun 2, 2022Class A Common StockCConversionAcquired+18,500$0.00$0534,768Direct
Jun 2, 2022Class A Common StockSSaleDisposed−18,500$6.34F3−$117,290516,268Direct
Jun 2, 2022Class A Common StockCConversionAcquired+500$0.00$0500Indirect
Jun 2, 2022Class A Common StockSSaleDisposed−500$6.34F5−$3,1700Indirect
Jun 2, 2022Class A Common StockCConversionAcquired+1,000$0.00$01,000Indirect
Jun 2, 2022Class A Common StockSSaleDisposed−1,000$6.35F7−$6,3500Indirect
Jun 2, 2022Class A Common StockCConversionAcquired+1,000$0.00$01,000Indirect
Jun 2, 2022Class A Common StockSSaleDisposed−1,000$6.34F9−$6,3400Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 2, 2022Class A Common StockCConversionDisposed−18,500$0.00$06,788,334Direct
Jun 2, 2022Class A Common StockMOption exerciseDisposed−31,250$0.00$0968,750Direct
Jun 2, 2022Class A Common StockCConversionDisposed−500$0.00$0543,500Indirect
Jun 2, 2022Class A Common StockCConversionDisposed−1,000$0.00$0537,000Indirect
Jun 2, 2022Class A Common StockCConversionDisposed−1,000$0.00$0133,875Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

This transaction was executed in multiple trades at prices ranging from $5.97 to $6.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F5

This transaction was executed in multiple trades at prices ranging from $6.05 to $6.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F7

This transaction was executed in multiple trades at prices ranging from $6.05 to $6.57. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F9

This transaction was executed in multiple trades at prices ranging from $5.91 to $6.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)